Skip to main content

Articles

Page 39 of 39

  1. Prostate cancer remains the most common malignancy among elderly men and the second leading cause of cancer death in the United States. Although several conventional therapies are currently available, they hav...

    Authors: Paul Pyo, Brandon Louie, Srinivas Rajamahanty, Muhammad Choudhury and Sensuke Konno
    Citation: Journal of Hematology & Oncology 2008 1:25
    Content type: Research Published on:

  2. The etiology of venous thromboembolism in young patients is frequently associated with hereditary coagulation abnormalities, immunologic diseases, and neoplasia. The advent of radiological advances, namely Com...

    Authors: Cannon Milani, Maria Constantinou, David Berz, James N Butera and Gerald A Colvin
    Citation: Journal of Hematology & Oncology 2008 1:24
    Content type: Case report Published on:

  3. Thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome (TTP-HUS) are related and uncommon disorders with a high fatality and complication rate if untreated. Plasma exchange therapy has been show...

    Authors: Mark Levandovsky, Danielle Harvey, Primo Lara and Ted Wun
    Citation: Journal of Hematology & Oncology 2008 1:23
    Content type: Research Published on:

  5. Antiandrogen withdrawal response is an increasingly recognized entity in patients with metastatic prostate cancer. To our knowledge, there have been no reports describing a durable radiologic improvement along wi...

    Authors: Yiu-Keung Lau, Manpreet K Chadha, Alan Litwin and Donald L Trump
    Citation: Journal of Hematology & Oncology 2008 1:21
    Content type: Case report Published on:

  6. This review summarizes phase I trial results of 11 drugs presented at the American Society of Clinical Oncology meeting held in Chicago IL from May 30 to June 3rd 2008: BMS-663513, CT-322, CVX-045, GDC-0449, G...

    Authors: Andrea Molckovsky and Lillian L Siu
    Citation: Journal of Hematology & Oncology 2008 1:20
    Content type: Review Published on:

  7. Excessive maturation of hematopoietic cells leads to a reduction of long-term proliferative capability during cord blood (CB) expansion. In this study, we report the effects of anit-CD52 (Alemtuzumab, Campath)...

    Authors: Che K Lim, Li Sun, Qi Feng, Ping Law, Wei T Chua, Shy N Lim and William YK Hwang
    Citation: Journal of Hematology & Oncology 2008 1:19
    Content type: Research Published on:

  8. Hepatocellular carcinoma is rare, but increasing in prevalence in the United States. Recent studies have shown that sorafenib, a multikinase inhibitor, can reduce tumor progression in patients with this cancer...

    Authors: Brian J So, Tanios Bekaii-Saab, Mark A Bloomston and Tushar Patel
    Citation: Journal of Hematology & Oncology 2008 1:18
    Content type: Case report Published on:

  9. We have analyzed t(12;21)(p13:q22) in an attempt to evaluate the frequency and prognostic significance of TEL-AML1 fusion gene in patients with childhood CD 10 positive B-ALL by fluorescence in situ hybridization...

    Authors: Eman Mosad, Hosny B Hamed, Rania M Bakry, Azza M Ezz-Eldin and Nesrine M Khalifa
    Citation: Journal of Hematology & Oncology 2008 1:17
    Content type: Research Published on:

  10. Breast cancer is the most common female cancer and the second most common cause of female cancer-related deaths in the United States. World-wide, more than one million women will be diagnosed with breast cance...

    Authors: David Chu and Janice Lu
    Citation: Journal of Hematology & Oncology 2008 1:16
    Content type: Review Published on:

  12. L-arginine is the common substrate for the two isoforms of arginase. Arginase I, highly expressed in the liver and arginase II mainly expressed in the kidney. Arginase I-producing myeloid derived suppressor ce...

    Authors: David J Tate Jr, Derek J Vonderhaar, Yupanqui A Caldas, Toye Metoyer, John R Patterson IV, Diego H Aviles and Arnold H Zea
    Citation: Journal of Hematology & Oncology 2008 1:14
    Content type: Research Published on:

  13. The most common semiquantitative method of evaluation of pulmonary lesions using 18F-FDG PET is FDG standardized uptake value (SUV). An SUV cutoff of 2.5 or greater has been used to differentiate between benign a...

    Authors: Majid Khalaf, Hani Abdel-Nabi, John Baker, Yiping Shao, Dominick Lamonica and Jayakumari Gona
    Citation: Journal of Hematology & Oncology 2008 1:13
    Content type: Research Published on:

  14. Amplification of the ERBB2 (Her-2/neu) oncogene, which occurs in approximately 25% of breast carcinomas, is a known negative prognostic factor. Available data indicate that a variable number of nearby genes on ch...

    Authors: Lydia Usha, Bita Tabesh, Larry E Morrison, Ruta D Rao, Kris Jacobson, April Zhu, Sanjib Basu and John S Coon
    Citation: Journal of Hematology & Oncology 2008 1:12
    Content type: Research Published on:

  15. In recent years, new treatment for renal cell carcinoma (RCC) has been a spotlight in the field of cancer therapeutics. With several emerging agents branded as 'targeted therapy' now available, both medical on...

    Authors: David Chu and Shenhong Wu
    Citation: Journal of Hematology & Oncology 2008 1:11
    Content type: Review Published on:

  16. Molecular characterisation of normal karyotype acute myeloid leukemia (NK-AML) allows prognostic stratification and potentially can alter treatment choices and pathways. Approximately 45–60% of patients with N...

    Authors: Angela YC Tan, David A Westerman, Dennis A Carney, John F Seymour, Surender Juneja and Alexander Dobrovic
    Citation: Journal of Hematology & Oncology 2008 1:10
    Content type: Short report Published on:

  17. Previous studies demonstrated Ganoderma lucidum polysaccharides (GL-PS), a form of bioactive β-glucan can stimulate the maturation of monocyte-derived dendritic cells (DC). The question of how leukemic cells espe...

    Authors: Wing Keung Chan, Christopher Ching Hang Cheung, Helen Ka Wai Law, Yu Lung Lau and Godfrey Chi Fung Chan
    Citation: Journal of Hematology & Oncology 2008 1:9
    Content type: Research Published on:

  18. In a departure from conventional strategies to improve treatment outcome for myeloid malignancies, we report the isolation of leukemia-specific peptides using a phage display library screened with freshly obta...

    Authors: Naomi Galili, Emmanuelle Devemy and Azra Raza
    Citation: Journal of Hematology & Oncology 2008 1:8
    Content type: Research Published on:

  19. To report the clinico-histopathologic features, management and outcome of Rosai-Dorfman disease of the orbit.

    Authors: Geeta K Vemuganti, Milind N Naik and Santosh G Honavar
    Citation: Journal of Hematology & Oncology 2008 1:7
    Content type: Research Published on:

  20. Histone deacetylase (HDAC) inhibitors are a new class of chemotherapeutic agents. Our laboratory has recently reported that phenylhexyl isothiocyanate (PHI), a synthetic isothiocyanate, is an inhibitor of HDAC...

    Authors: Quanyi Lu, Xianghua Lin, Jean Feng, Xiangmin Zhao, Ruth Gallagher, Marietta Y Lee, Jen-Wei Chiao and Delong Liu
    Citation: Journal of Hematology & Oncology 2008 1:6
    Content type: Research Published on:

  22. Lipoic acid (LA), a potent antioxidant, has been used as a dietary supplement to prevent and treat many diseases, including stroke, diabetes, neurodegenerative and hepatic disorders. Recently, potent anti-tumo...

    Authors: Elangovan Selvakumar and Tze-chen Hsieh
    Citation: Journal of Hematology & Oncology 2008 1:4
    Content type: Research Published on:

  24. Detection of circulating tumor cells (CTC) in the blood of cancer patients may have prognostic and predictive significance. However, background expression of 'tumor specific markers' in peripheral blood mononu...

    Authors: Fanglei You, Lisa A Roberts, S Peter Kang, Raquel A Nunes, Cinara Dias, J Dirk Iglehart, Natalie A Solomon, Paula N Friedman and Lyndsay N Harris
    Citation: Journal of Hematology & Oncology 2008 1:2
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us